ReviewJournal of medical virology2020
Hepatic complications of COVID-19 and its treatment.
Review in Journal of medical virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 129 citations in OpenAlex.
- COVID-19 Infection, Drugs, and Liver Injury.Journal of clinical medicine · 2025Review
- Article
- Eosinophils and COVID-19: Insights into immune complexity and vaccine safety.Clinical and translational allergy · 2025Review
- Could Remdesivir be used in the Presence of Elevated Liver Enzymes Secondary to COVID-19 Infection in Children? A Case Report.Tanaffos · 2025Article
- Hepatitis B virus associated with severe acute respiratory syndrome coronavirus 2 infection: a case report.Journal of medical case reports · 2025Article
- The effect of SARS-CoV-2 infection on the liver function tests: a systematic review and meta-analysis of observational studies.Przeglad gastroenterologiczny · 2025Review
- Comparison of clinical, laboratory and radiological characteristics between COVID-19 and Chlamydia psittaci pneumonia: a multicenter retrospective study.Scientific reports · 2024Article
- Review
- Occupational exposure protection and perioperative management of sudden infectious diseases from the perspective of COVID-19.The Journal of international medical research · 2024Review
- Severe COVID-19 in HIV/Leishmania infantum coinfected patient: a successfully managed case report.BMC infectious diseases · 2024Article
- Impact of non-emergency surgical timing on postoperative recovery quality in mild or asymptomatic SARS-CoV-2 infected patients: a grouped cohort study.BMC anesthesiology · 2024Article
- Acute hypothermia in a patient with COVID-19: a case report and summary of the evidence.Annals of medicine and surgery (2012) · 2024Article
- COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?International journal of molecular sciences · 2024Review
- Review
- Nephrogenic diabetes insipidus in a geriatric patient affected by SARS-CoV-2: complexity of a diagnosis, complexity of a virus.Access microbiology · 2024Article
- Article
- COVID-19 associated liver injury: An updated review on the mechanisms and management of risk groups.Liver research (Beijing, China) · 2023Review
- COVID-19 and liver injury: Pathophysiology, risk factors, outcome and management in special populations.World journal of hepatology · 2023Review
- Liver manifestations in COVID-19 patients: A review article.World journal of clinical cases · 2023Review
- Relation of COVID-19 with liver diseases and their impact on healthcare systems: The Portuguese case.World journal of gastroenterology · 2023Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is highly contagious and has a variety of clinical manifestations, it can affect a number of other organs in addition to the lungs, and liver injury may occur. Severe acute respiratory syndrome coronavirus 2 can cause liver injury through systemic inflammatory response syndrome, cytokine storms, ischemia-reperfusion injury, side effects of treatment drugs, and underlying liver disease and can attack liver cells directly via angiotensin-converting enzyme 2. Clinical studies have found that liver injury in COVID-19 patients mainly manifests as abnormal liver biochemical indicators, but there have been no reports of liver failure caused by this disease. The number of COVID-19 patients with liver injury is increasing, and the incidence of liver injury in COVID-19 patients with severe disease are higher than in patients with mild disease. Liver injury may be a risk factor, which worsens in patients with COVID-19, and hence it is necessary to pay attention to the occurrence of liver injury in the diagnosis and treatment of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.